share_log

Needham Maintains Buy on Blueprint Medicines, Raises Price Target to $133

Needham Maintains Buy on Blueprint Medicines, Raises Price Target to $133

Needham維持Blueprint Medicines的買入評級,將價格目標上調至133美元。
Benzinga ·  08/05 15:13  · 評級/大行評級

Needham analyst Ami Fadia maintains Blueprint Medicines (NASDAQ:BPMC) with a Buy and raises the price target from $130 to $133.

Needham分析師 Ami Fadia 維持對blueprint medicines(納斯達克代碼:BPMC)的買入評級,將目標股價從130美元上調至133美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論